Revance Therapeutics (NASDAQ:RVNC) is a biotechnology company headquartered in Nashville, Tennessee, focused on the development and commercialization of innovative aesthetic and therapeutic products. The company’s core expertise lies in injectable neuromodulators and dermal fillers, leveraging advanced proprietary platforms to address both cosmetic and medical needs. Revance’s lead product, DaxibotulinumtoxinA for Injection (DAXI), targets facial lines and wrinkles and represents one of the most significant advancements in neuromodulator technology in recent years.
In addition to its flagship aesthetic offering, Revance is advancing a diversified pipeline of therapeutic candidates. These include indications such as chronic migraine, cervical dystonia and plantar fasciitis, where extended-duration neuromodulation could provide sustained relief. The company also explores innovative applications of its Resilient Hyaluronic Acid (RHA®) dermal filler technology, designed to mimic the natural movement and resilience of facial tissue while providing longer-lasting aesthetic results.
Since its founding in 2011, Revance has expanded its footprint beyond the U.S., forging partnerships and regulatory pathways in Europe, Asia and Latin America. The company’s global strategy combines direct commercial efforts with collaborations that capitalize on local market expertise for distribution, regulatory approval and patient access. Manufacturing operations are supported by strategic relationships with contract development and manufacturing organizations (CDMOs) to ensure scale and quality compliance.
Leadership at Revance is headed by President and Chief Executive Officer Mark J. Foley, who brings extensive experience in biotechnology product development and commercialization. Under Foley’s guidance, the company has navigated complex clinical trials, secured key regulatory milestones and established a growing commercial presence. Revance’s management team includes seasoned professionals in research and development, regulatory affairs, medical affairs and commercial operations, all aligned to drive the company’s mission of delivering safe, effective and long‐lasting treatments to patients and consumers worldwide.
